+

WO1997049405A1 - Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine - Google Patents

Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine Download PDF

Info

Publication number
WO1997049405A1
WO1997049405A1 PCT/US1997/011205 US9711205W WO9749405A1 WO 1997049405 A1 WO1997049405 A1 WO 1997049405A1 US 9711205 W US9711205 W US 9711205W WO 9749405 A1 WO9749405 A1 WO 9749405A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
weight
acid
derivative
mixtures
Prior art date
Application number
PCT/US1997/011205
Other languages
English (en)
Inventor
Nigel John Leeves
François Riahi
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to BR9709997A priority Critical patent/BR9709997A/pt
Priority to HU9903835A priority patent/HUP9903835A3/hu
Priority to AU36438/97A priority patent/AU3643897A/en
Priority to IL12742697A priority patent/IL127426A0/xx
Priority to EP97933190A priority patent/EP0973522A1/fr
Priority to JP10503550A priority patent/JPH11513037A/ja
Priority to NZ333180A priority patent/NZ333180A/xx
Publication of WO1997049405A1 publication Critical patent/WO1997049405A1/fr
Priority to NO986042A priority patent/NO986042L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to pharmaceutical compositions for topical application.
  • the present invention relates to pharmaceutical compositions for topical application in the form of a gel comprising a non-steroidal anti-inflammatory drug and a xanthine derivative.
  • the compositions of the present invention are useful as analgesics and anti-inflammatories.
  • Xanthine derivatives are known for use in pharmaceutical compositions.
  • Caffeine is a particularly well known xanthine derivative.
  • Caffeine, or 3,7-dihydro-l ,3,7-trimethyl-lH-purine-2,6- dione, has the structural formula:
  • Caffeine has been used alone, intravenously, in the treatment of headaches and has also been used in combination with selected drugs.
  • One of the types of topical formulations that caffeine has been used in is a topical gel.
  • a commercial aqueous gel product containing caffeine for topical treatment of skin is Percutafeine gel, supplied by Laboratories Pierre Fabre Sante, Paris, France, which contains 4% by weight of caffeine and which is used to treat obesity.
  • EP-A-0105635 (Han & Roehrs, published 18 April 1984) relates to ophthalmic aqueous gel compositions for reducing ocular stinging comprising an acidic anti-inflammatory agent and a xanthine derivative.
  • Ibuprofen i.e. 2-(4-isobutylphenol) propionic acid
  • Ibuprofen is well known non- steroidal anti-inflammatory drug for use in oral compositions as a therapeutic agent having analgesic, anti-inflammatory and anti-pyretic activity. It is often used as an alternative to aspirin (i.e. acetyl salicylic acid) and paracetamol, in the treatment of pain such as headache, toothache and especially when associated with inflammation in, for example, rheumatic diseases.
  • Ibuprofen is also known for use in aqueous gel compositions for topical application to the skin.
  • GB-A-2134786 discloses oral pharmaceutical compositions comprising a non-steroidal anti-inflammatory drug (NSAID) analgesic, anti-inflammatory drug active such as ibuprofen, together with caffeine.
  • NSAID non-steroidal anti-inflammatory drug
  • EP-A-0105635 discloses ophthalmic compositions which may be aqueous solutions, suspensions or gels comprising an acidic anti- inflammatory agent, such as ketoprofen, and a xanthine derivative, such as caffeine. There are no examples in this document of aqueous gel compositions containing a xanthine derivative and a non-steroidal anti-inflammatory drug.
  • aqueous gel composition for topical application to the skin comprising a combination of a xanthine derivative such as caffeine and non-steroidal analgesic/anti- inflammatory drug such as ibuprofen, which delivers analgesic or anti- inflammatory efficacy.
  • a xanthine derivative such as caffeine
  • non-steroidal analgesic/anti- inflammatory drug such as ibuprofen
  • a topical gel composition comprising:
  • a non- steroidal anti-inflammatory drug selected from a propionic acid derivative, acetic acid derivative, fenamic acid derivative, biphenylcarboxylic acid derivative and an oxicam, and salts thereof, and mixtures thereof;
  • Rl, R2 and R3 are each independently selected from a hydrogen atom, a methyl or ethyl group, and at least two of Rl , R2 and R3 are methyl or ethyl groups; and mixtures thereof;
  • compositions of the present invention exhibit analgesic and anti- inflammatory activity and improved product stability and clarity.
  • compositions of the present invention comprise a non- steroidal anti-inflammatory drug, a xanthine derivative, a gelling agent, a cosolvent for the non-steroidal anti-inflammatory agent and the xanthine derivative and water.
  • compositions of the present invention are gels which have improved clarity and stability.
  • the compositions are formulated as clear gels.
  • the term "clear" is intended to have an ordinary dictionary meaning, that is, transparent and free from obscurity.
  • Product clarity can be measured using a visible range spectrophotometer. Using this equipment the percent transmittance of the sample at 450 nm is measured by calibration against a reference sample of Ethanol B100 as 100% transmittance.
  • Percent transmittance values for the gel compositions according to the present invention are preferably greater than 70% when first made, preferred compositions herein displaying 80% transmittance values after storage for at least four weeks at 37°C.
  • a first essential component of the compositions herein is a non- steroidal anti-inflammatory agent selected from a propionic acid derivative, an acetic acid derivative, a fenamic derivative, a biphenylcarboxylic acid derivative and an oxicam derivative, and salts thereof, and mixtures thereof.
  • non-steroidal anti-inflammatory agent as used herein is intended to mean any non- narcotic analgesic non-steroidal anti-inflammatory compound, including the pharmaceutically acceptable non-toxic salts thereof, falling within one of the five structural categories above.
  • propionic acid derivative as defined herein means non- narcotic analgesics/non-steroidal anti-inflammatory drugs having a free -CH(CH3)COOH or -CH2CH2COOH group or a combination thereof (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g. -CH(CH3)COCrNa+ or -CH2CH2COO"Na+), typically attached directly or via a carbonyl function to a ring system, preferably to an aromatic ring system.
  • a pharmaceutically acceptable salt group e.g. -CH(CH3)COCrNa+ or -CH2CH2COO"Na+
  • Suitable propionic acid derivatives for use herein include, but are not limited to, ibuprofen, naproxen, benoxaprofen, flurbiprofen, indoprofen, fenoprofen, ketoprofen, fenbufen and fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid and bucloxic acid.
  • Structurally related propionic acid derivatives having similar analgesic and anti- inflammatory properties are also intended to be encompassed by this group.
  • any of the foregoing compounds may be utilized in the form of their pharmaceutically-acceptable salt forms, e.g. , sodium salts, potassium salts, and the like, and such salts are intended to be included.
  • Particularly preferred propionic derivatives for use herein include ibuprofen, naproxen, naproxen sodium, flurbiprofen, fenoprofen, ketoprofen, suprofen, fenbufen and fluprofen, especially ibuprofen.
  • acetic acid derivatives as used herein means non-narcotic analgesics/non-steroidal anti-inflammatory drugs having a free - CH2COOH group (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g. -CH2COO ⁇ Na + ), typically attached directly to a ring system, preferably to an aromatic or heteroaromatic ring system.
  • a pharmaceutically acceptable salt group e.g. -CH2COO ⁇ Na +
  • acetic acid derivatives for use herein include, but are not limited to, indomethacin, sulindac, tolmetin, diclofenac, fenclofenac, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac and oxepinac.
  • Structurally related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
  • fumamic acid derivatives as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:
  • the fenamic acid derivatives suitable for use herein include, but are not limited to, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. Structurally realted fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
  • Representative members of the fenamic group include mefenamic acid, meclofenamate sodium (meclofenamic acid, sodium salt) and flufenamic acid.
  • biphenylcarboxylic acid derivatives as used herein means non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:
  • biphenylcarboxylic acid derivatives for use herein include, but are not limited to, diflunisal and flufenisal. Structurally realted biphenylcarboxylic acid derivtiaves having simipar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.
  • oxicams as defined herein means non-narcotic analgesics/non-steroidal anti-inflammatory drugs which have the general formula:
  • R is an aryl or heteroaryl ring system.
  • Suitable oxicams for use herein include, but are not limited to, piroxicam, sudoxicam, and isoxicam. Structurally related oxicams having similar analgesic and anti- inflammatory properties are also intended to be encompassed by this group.
  • the propionic acid derivatives are most preferred for use in the compositions herein, and especially ibuprofen.
  • the non-steroidal anti-inflammatory agent is present in the compositions of the present invention at a level of from about 0.1 % to about 20% , preferably from about 0.1 % to about 15% , especially from about 1 % to about 10% by weight of composition.
  • a second essential component of the compositions of the present invention is a xanthine derivative having the general formula:
  • Rj , R2 and R3 are each independently selected from a hydrogen atom, a methyl or ethyl group, and at least two of Ri , R2 and R3 are methyl or ethyl groups, and mixtures thereof.
  • the xanthine derivative is generally present herein at a level of from about 0.1 % to about 10% , especially from about 1 % to about 5% by weight of composition.
  • Particularly preferred for use herein are methyl and ethyl derivatives of xanthine.
  • Examples of xanthine derivatives include theophylline, which has methyl groups at the 1 and 3 positions, caffeine, which has methyl groups at the 1 ,3, and 7 positions, and theobromine which has methyl groups at the 3 and 7 positions.
  • Preferred herein in combination with the non-steroidal anti- inflammatory drug from the viewpoint of enhancing analgesic and/or anti-inflammatory activity is caffeine.
  • a third essential ingredient herein is a gelling agent for forming a gel in the aqueous base of the compositions of the present invention.
  • the gelling agent is generally present in the compositions herein at a level of from about 0.1 % to about 10%, preferably from about 0.5% to about 5% , more preferably from about 0.5% to about 3% by weight.
  • Suitable gelling agents for use herein include crosslinked polymeric gelling agents. These can be obtained by the polymerisation or copolymerisation of appropriate monomers together with a suitable crosslinking agent.
  • Suitable monomers for use in the crosslinked polymeric gelling agents include unsaturated, polymerizable carboxyl-containing monomers.
  • Monomers for use herein can be monoethyleneically or polyethyleneically unsaturated. Suitable monomers of this type include acrylic acid, methacrylic acid, ethacrylic acid, beta-methacrylic acid (crotonic acid), cis-alpha-methylcrotonic acid (angelic acid), trans- alkpha-methyl-crotonic acid (tiplic acid), alpha-butylcrotonic acid, alpha-phenylacrylic acid, alpha-benzylacrylic acid, alpha- cyclohexylacrylic acid, beta-phenylacrylic acid (cinnamic acid), coumaric acid (ortho-hydrocinnamic acid), umbellic acid (p- hydroxycoumaric acid) and the like. Mixtures of these monomers can also be used.
  • Preferred monomers for use herein are carboxyl-containing monoethyleneically unsaturated monomers, especially acrylic acid.
  • Copolymers prepared from one or more of the above monomers together with one or more other monomers can also be used as long as the resulting copolymers are safe and effective for use as gelling agents in the compositions herein.
  • Suitable crosslinking agents for use herein include non-polyalkenyl polyether difuntional crosslinking monomers, polyalkenyl polyether crosslinking agents and diolefinic non-hydrophilic macromeric crosslinking agents.
  • Suitable non-polyalkenyl polyether difunctional crosslinking agents include divinyl glycol, 2,3-dihydroxyhexa-l ,5,-diene, 2,5-dimethyl- 1 ,5-hexadiene, divinylbenzene, N,N-diallylacrylamide, N,N- diallylmethacrylamide and the like.
  • Suitable diolefinic non-hydrophilic macromeric crosslinking agents include those having molecular weights of from about 400 to about 8,000 such as insoluble di- and polyacrylates and methacrylates of diols and polyols, diisocyanate-hydroxyalkyl acrylate or methacrylate reaction products, and reaction products of isocyanate terminated prepolymers derived from polyester diols, polyether diols or polysiloxane diols with hydroxyalkylmethacrylates, and the like.
  • the crosslinking agent is generally present at a level in the range of from about 0.05% to about 5% , preferably from about 0.1 % to about 5% , especially from about 0.75 % to about 2% by weight of the polymer.
  • Preferred gelling agents for use herein are polyalkenyl polyether- crosslinked polymers of carboxyl-containing monethyleneically unsaturated monomers. More preferred gelling agents for use herein are polyalkenyl polyether-crosslinked polymers of acrylic acid. Especially preferred gelling agents for use herein are polyallyl sucrose or polyallyl pentaerythritol-crosslinked polymers of acrylic acid.
  • Examples of such polymers include those commercially available under the tradename Carbopol, such as Carbopol 934, 934P, 940, 941 , 974P, 980, 981 , manufactured by B.F. Goodrich Chemical Company, U.S.A.
  • Carbopol 980 which is a polyallylsucrose-crosslinked polymer of acrylic acid.
  • hydrophobically-modified carboxylate monomers such as C1-C30 alkyl substituted carboxylate-containing monomers, such as C1-C30 acrylic acid (acrylate) monomers.
  • C1-C30 alkyl substituted carboxylate-containing monomers such as C1-C30 acrylic acid (acrylate) monomers.
  • These can be used to form hydrophobically modified, cross-linked copolymers wherein the modified polymeres have amphipathic properties.
  • examples include copolymers of acrylic acid and C1-C30 alkyl substituted acrylic acid, such as those available under the Trade Name Carbopol 1342 and Pemulen TR-1 (CTFA Designation: Acrylates/ 10-30 Alkyl Acrylate Crosspolymer).
  • CTFA Designation Acrylates/ 10-30 Alkyl Acrylate Crosspolymer.
  • Combinations of the polyalkenyl polyether cross-linked acrylic acid polymer and the hydrophobically modified cross-linked acrylic acid polymer are also suitable for use herein.
  • Neutralizing agents suitable for use herein include sodium hydroxide, potassium hydroxide, ammonium hydroxide, monoethanolamine, diethylamine, diisopropanolamine, diethanolamine and triethanolamine.
  • a preferred neutralizing agent for use herein is diethylamine.
  • the neutralizing agent is preferably present in a level from about 0.1 % to about 5% , preferably from about 2% to about 5% by weight.
  • Suitable gelling agents for use herein are lower alkyl ethers of cellulose.
  • the lower alkyl ether of cellulose suitable for use herein I I results fom at least partial substitution of the same or different lower alkyl ether groups for a plurality of hydroxyl groups of cellulose.
  • the lower alkyl ether groups may be substituted by substituents. Preferred examples of such substituents are a hydroxyl group, and alkali metal carboxylate groups such as sodium carboxylate group.
  • Examples of the optionally substitued lower alkyl groups are a methyl group, hydroxy lower alkyl groups having 2 or 3 carbon atoms, and carboxylate groups resulting from substitution of an alkali metal for the hydrogen atom of the carboxyl group of a carboxy lower alkyl group having 2 or 3 carbon atoms.
  • Specific examples of the hydroxy lower alkyl groups are B-hydroxyethyl and B-hydroxypropyl groups
  • specific examples of the carboxylate groups are carboxylate groups resulting from substitution of an alkali metal for a carboxymethyl, a- carboxyethyl or B-carboxyethyl group.
  • lower alkyl ethers of cellulose include methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethylhydroxyethyl cellulose, and sodium carboxymethyl cellulose.
  • Preferred cellulose ethers for use herein are methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose.
  • the lower alkyl ethers of cellulose can be used either singly or in combination with each other, or with other gelling agents.
  • the gelling agent used herein has a viscosity (Brookfield RVT, Spindle No. 7, 20 rpm, 20°C, undiluted) of at least about 4,000 mPa.s, preferably at least about 10,000 mPa.s.
  • Preferred gelling agents for use herein have an average molecular weight in the range from about 1 ,000,000 to about 4,500,000.
  • a fourth essential component of the compositions herein is a cosolvent for the xanthine derivative and the non-steroidal anti-inflammatory drug.
  • Suitable cosolvents for use herein include any solvent which is miscible with water and which is suitable for topical application which aids in the solubilisation of the xanthine derivative and the non- steroidal anti-inflammatory drug.
  • Suitable cosol vents include straight chain and branched chain alcohols having from 1 to 6 carbon ⁇ toms, and mixtures thereof.
  • the preferred cosolvent for use hereii is a straight chain alcohol having from 1 to 4 carbon atoms, espe ially ethanol.
  • the solvent is generally present herein in a level of from about 5 % to about 60% by weight.
  • compositions herein also comprise water, generally from abou. 10% to about 90% , preferably from about 30% to about 80%, more preferably from about 30% to about 60% by weight of water.
  • the gel compositions preferably have a pH of from about 3 to about 8, more preferably from about 4 to about 7, more preferably about 7, and a viscosity of from about 10,000 to about 50,000, preferably from about 20,000 to about 40,000 cps (Brookfield RVT, 20°C, Spindle 7, 20 rpm, undiluted)
  • compositions herein can comprise a wide range of optional ingredients.
  • a surfactant can be present in the compositions herein.
  • Suitable surfactants for use herein include anionic, nonionic, cationic, amphoteric and zwitterionic surfactants and mixtures thereof. When present the surfactant is preferably at a level of up to about 1 % by weight of composition.
  • compositions herein can contain cooling agents such as menthol.
  • menthol is present in the compositions herein, when used, at a level of from about 0.1 % to about 5 % , preferably from about 1 % to about 5 % by weight.
  • compositions herein can additionally include preservatives.
  • preservatives can be water-soluble or solubilizable preservatives such as DMDM Hydantoin (RTM), Germall (RTM) 115, methyl, ethyl, propyl and butyl esters of hydrobenzoic acid, benzoic acid, Euxyl (RTM) K400, Bronopol (RTM) (2-bromo-2-nitropropane-l ,3-dioI), sodium benzoate, chlorhexadine, benzalkonium chlorides and 2-phenoxyethanol, Cetrimide, potassium sorbate and thiomersal.
  • Preferred preservatives for inclusion in the present invention are methyl and propyl parabens. In general, amounts of from about 0.005% to about 0.5 % are suitable herein with amounts of from about 0.01 % to about 0.1 % being preferred.
  • compositions of the invention may comprise additional therapeutic agents including steroids, antibiotics, antiinfectives and antiallergics such as antihistamines, and other ingredients for modifying the appearance or aesthetic propertise of the composition, such as fragrances, colouring agents, and the like.
  • Carbopol 980 1 2 3 2 3 2
  • Methyl Salicylate 0 0 3 0 0
  • compositions can be prepared as follows.
  • the Carbopol is dissolved in water with stirring and then the caffeine is added, followed by addition of propylene glycol.
  • the ibuprofen is dissolved in the ethanol and the resulting premix is added to the main batch.
  • the diethylamine is finally added quickly to produce the required gel.
  • methyl salicylate When methyl salicylate is part of the final composition it is added to the ethanol before the ibuprofen.
  • menthol When menthol is part of the final composition, menthol is dissolved in a small amount of ethanol before being added to the main batch.
  • the caffeine is added to the main batch just before the diethylamine.
  • compositions of the examples exhibit excellent product stability and clarity and excellent analgesic and anti-inflammatory activity when applied to the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une composition d'un gel topique, comportant: (a) de 0,1 % environ à 10 % en poids d'un médicament anti-inflammatoire non stéroïde (MAINS), choisi dans un groupe comprenant des dérivés de l'acide propionique, de l'acide acétique, de l'acide fénamique, de l'acide biphénylcarboxylique, et un oxicam, ainsi que les sels de ces produits et leurs mélanges; (b) de 0,1 % environ à 10 % environ en poids d'un dérivé de xanthine ayant la formule générale (I), où R1, R2 et R3 sont sélectionnés, chacun indépendamment l'un de l'autre, parmi un atome d'hydrogène, un groupe méthyle ou éthyle, et, parmi R1, R2 et R3, au moins deux sont des groupes méthyle ou éthyle, ou des mélanges de ceux-ci; (c) de 0,5 % environ à 10 % environ en poids d'un agent gélifiant; (d) de 5 % environ à 60 % environ en poids d'un cosolvant utilisé pour ledit médicament anti-inflammatoire non stéroïde et ledit dérivé de xanthine; (e) de 10% environ à 90 % environ en poids d'eau. Les compositions décrites dans l'invention offrent une stabilité, une limpidité ainsi qu'une activité analgésique et anti-inflammatoire accrue.
PCT/US1997/011205 1996-06-27 1997-06-24 Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine WO1997049405A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR9709997A BR9709997A (pt) 1996-06-27 1997-06-24 Composição em gel tópica contendo ma combinação de um nsaid e um derivado de xantina
HU9903835A HUP9903835A3 (en) 1996-06-27 1997-06-24 Topical gel composition containing a combination of a nsaid and a xanthine derivative
AU36438/97A AU3643897A (en) 1996-06-27 1997-06-24 Topical gel composition containing a combination of a nsaid and a xanthine derivative
IL12742697A IL127426A0 (en) 1996-06-27 1997-06-24 Topical gel composition containing a combination of a nsaid and xanthine derivative
EP97933190A EP0973522A1 (fr) 1996-06-27 1997-06-24 Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine
JP10503550A JPH11513037A (ja) 1996-06-27 1997-06-24 非ステロイド抗炎症剤およびキサンチン誘導体の組み合わせを含有する局所用ゲル組成物
NZ333180A NZ333180A (en) 1996-06-27 1997-06-24 Topical aqueous gel composition containing a combination of a non-steroidal anti-inflammatory drug, a xanthine derivative, a gelling agent, water and a cosolvent
NO986042A NO986042L (no) 1996-06-27 1998-12-22 Topisk gelsammensetning inneholdende en kombinasjon av NSAID og et xantinderivat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9613457.2 1996-06-27
GBGB9613457.2A GB9613457D0 (en) 1996-06-27 1996-06-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
WO1997049405A1 true WO1997049405A1 (fr) 1997-12-31

Family

ID=10795959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/011205 WO1997049405A1 (fr) 1996-06-27 1997-06-24 Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine

Country Status (14)

Country Link
EP (1) EP0973522A1 (fr)
JP (1) JPH11513037A (fr)
KR (1) KR20000022245A (fr)
AU (1) AU3643897A (fr)
BR (1) BR9709997A (fr)
CA (1) CA2258199A1 (fr)
CZ (1) CZ409198A3 (fr)
GB (1) GB9613457D0 (fr)
HU (1) HUP9903835A3 (fr)
IL (1) IL127426A0 (fr)
NO (1) NO986042L (fr)
NZ (1) NZ333180A (fr)
TR (1) TR199802701T2 (fr)
WO (1) WO1997049405A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856310A3 (fr) * 1997-02-04 2000-01-19 Senju Pharmaceutical Co., Ltd. Méthode pour stabiliser d'acide arylcarboxylique, stabilisateur utilisable pour celle-ci et solution contenant une acide arylcarboxylique stabilisée
WO2000030715A1 (fr) * 1998-11-25 2000-06-02 Chinoin Gyógyszer És Vegyészeti Composition contenant un analgesique et une xanthine ou un derive de xanthine
WO2001002015A1 (fr) * 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Composition et methode d'absorption transdermique amelioree d'anti-inflammatoires non steroidiens
US7919125B2 (en) 2001-06-20 2011-04-05 Metaproteomics, Llc Modulation of inflammation by hops fractions and derivatives
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105635A2 (fr) * 1982-09-07 1984-04-18 Alcon Laboratories, Inc. Formulation soulageante de compositions ophtalmiques aqueuses non irritantes pour des agents thérapeutiques oculaires
WO1996030022A1 (fr) * 1995-03-29 1996-10-03 Alcon Laboratories, Inc. Formulations acidiferes topiques ophtalmiques comportant un medicament acide, de la vitamine e tpgs, du chlorure de benzalkonium et de la cafeine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105635A2 (fr) * 1982-09-07 1984-04-18 Alcon Laboratories, Inc. Formulation soulageante de compositions ophtalmiques aqueuses non irritantes pour des agents thérapeutiques oculaires
WO1996030022A1 (fr) * 1995-03-29 1996-10-03 Alcon Laboratories, Inc. Formulations acidiferes topiques ophtalmiques comportant un medicament acide, de la vitamine e tpgs, du chlorure de benzalkonium et de la cafeine

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856310A3 (fr) * 1997-02-04 2000-01-19 Senju Pharmaceutical Co., Ltd. Méthode pour stabiliser d'acide arylcarboxylique, stabilisateur utilisable pour celle-ci et solution contenant une acide arylcarboxylique stabilisée
US6274592B1 (en) 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
EP1389469A1 (fr) * 1997-02-04 2004-02-18 Senju Pharmaceutical Co., Ltd. Méthode pour stabiliser d'acide arylcarboxylique, stabilisateur utilisable pour celle-ci et solution contenant une acide arylcarboxylique stabilisée
US7320985B2 (en) 1997-02-04 2008-01-22 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
WO2000030715A1 (fr) * 1998-11-25 2000-06-02 Chinoin Gyógyszer És Vegyészeti Composition contenant un analgesique et une xanthine ou un derive de xanthine
WO2001002015A1 (fr) * 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Composition et methode d'absorption transdermique amelioree d'anti-inflammatoires non steroidiens
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US7919125B2 (en) 2001-06-20 2011-04-05 Metaproteomics, Llc Modulation of inflammation by hops fractions and derivatives
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface

Also Published As

Publication number Publication date
NZ333180A (en) 2000-09-29
GB9613457D0 (en) 1996-08-28
CA2258199A1 (fr) 1997-12-31
HUP9903835A3 (en) 2001-03-28
CZ409198A3 (cs) 1999-04-14
JPH11513037A (ja) 1999-11-09
TR199802701T2 (xx) 1999-03-22
IL127426A0 (en) 1999-10-28
HUP9903835A2 (hu) 2000-10-28
NO986042L (no) 1999-02-26
KR20000022245A (ko) 2000-04-25
EP0973522A1 (fr) 2000-01-26
AU3643897A (en) 1998-01-14
BR9709997A (pt) 1999-08-10
NO986042D0 (no) 1998-12-22

Similar Documents

Publication Publication Date Title
US10821075B1 (en) Compositions for topical application of a medicaments onto a mammalian body surface
CA2309178C (fr) Compositions topiques pour l'administration de medicaments anti-inflammatoires non steroidiens
CA2402267C (fr) Combinaisons anti-infectieuses de principes actifs et leur utilisation dans le traitement topique de mycoses des ongles des orteils et des doigts
AU2013323766B2 (en) Topical ketoprofen composition
EP2506831B1 (fr) Suspension de nanoparticules contenant un polymère de type carboxyvinyle
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
WO1993000873A1 (fr) Procede et composition permettant d'administrer du diclofenac par voie transdermique
WO1994005330A1 (fr) Produits pour pulverisateur nasal
ES2590258T3 (es) Preparación antiinflamatoria y analgésica para uso externo
WO2012087749A1 (fr) Composition pour administration transdermique de médicament anti-inflammatoire non stéroïdien
EP0973522A1 (fr) Composition de gel topique contenant une combinaison d'un mains et d'un derive de xanthine
WO2010100252A1 (fr) Procédé de dissolution d'un agent antifongique, et compositions ayant une concentration élevée en agent antifongique, adaptées pour une application aux ongles
CN106604717A (zh) 局部用双氯芬酸钠组合物
ES2301807T3 (es) Compuestos de amoniociclodextrina cuaternizados.
WO1999012545A2 (fr) Medicaments contenant acyclovir
JP2019038795A (ja) 新規眼科用組成物および使用方法
EP1496868A1 (fr) Compositions pharmaceutiques de carbidopa et de levodopa a liberation controlee
EP4087559A1 (fr) Compositions topiques contenant du rofécoxib, et leurs procédés de fabrication et méthodes d'utilisation
EP1613300A2 (fr) Formulations topiques stabilisees contenant du ketoprofene
CA2384717A1 (fr) Traitement topique utilise dans la prevention d'infections oculaires
CN1223584A (zh) 含非类固醇抗炎药和黄嘌呤衍生物组合的局部外用的凝胶组合物
ES2225301T3 (es) Composiciones farmaceuticas para la administracion topica en la cavidad oral de farmacos antiinflamatorios no esteroideos utiles para las terapias antiinflamatorias y analgesicas estomatologicas, de la boca y de la cavidad oral.
AU2004296539B2 (en) UV-stable, liquid or semi-solid transdermal administration form comprising a photosensitive active ingredient
WO2020086038A2 (fr) Compositions topiques comprenant une combinaison de tolpérisone et d'inhibiteur sélectif de cox-2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195824.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 333180

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1199801027

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PV1998-4091

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2258199

Country of ref document: CA

Ref document number: 2258199

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997933190

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 503550

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/02701

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1019980710665

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000086

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: PV1998-4091

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997933190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980710665

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980710665

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-4091

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1997933190

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载